 Home > Active Ingredient News > Antitumor Therapy > Junshi Biologics completed the rolling submission of the marketing application of Teriprizumab to the U.S. FDA for the treatment of nasopharyngeal carcinoma

Junshi Biologics completed the rolling submission of the marketing application of Teriprizumab to the U.S. FDA for the treatment of nasopharyngeal carcinoma

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

what safety precautions

anti mog antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Beijing 2021 Nian 9 1st, Jun real biological ( 1877.

Teriplizumab is an anti- PD-1 monoclonal antibody

The breakthrough therapy is derived from the "Food and Drug Administration Safety and Innovation Act" ( FDASIA ).

Journal of Clinical Oncology ASCO Na ture Medicine

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area and is one of the common malignant tumors of the head and neck

The world's first immune checkpoint inhibitor immunity approved for the treatment of nasopharyngeal cancer

Dr.

C o herus CEO Denny Lanfear Tumor Immunity

-- over--

About Terry Plymouth monoclonal antibody injection (extension beneficial ^® )

About Terry Plymouth monoclonal antibody injection (extension beneficial about Terry Plymouth monoclonal antibody injection (extension beneficial ^®^® ® ) )

Terry Plymouth monoclonal antibody injection (extension beneficial ^® ), as approved the listing of China's first domestically to PD-1 monoclonal antibody drugs targeting of national science and technology major special project support

Terry Plymouth monoclonal antibody injection (extension beneficial ^® ® ), as approved the listing of China's first domestically to PD-1 as a target for monoclonal antibody drugs, access to national major science and technology projects to support

In February 2021 , the marketing application for new indications for the first-line treatment of teriprizumab combined with cisplatin and gemcitabine for patients with locally recurring or metastatic nasopharyngeal carcinoma was accepted by the NMPA .

Terry Plymouth mAb since 2016 the beginning of clinical research and development, has been carried out around the world covering more than one 5 indication for the 30 number of clinical studies, and actively explore the product in melanoma, nasopharyngeal carcinoma, urothelial carcinoma, The efficacy and safety of lung cancer, gastric cancer , esophageal cancer, liver cancer, cholangiocarcinoma, breast cancer , kidney cancer and other indications, and joint therapy cooperation with leading innovative pharmaceutical companies at home and abroad are also underway.

About Junshi Biological About Junshi Biological

Jun real biological ( 688180.

Relying on the protein engineering core platform technology, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti- PD-1 monoclonal antibody NMPA approval, the domestic anti- PCSK9 monoclonal antibody NMPA clinical application approval, and the world's first treatment The tumor anti- BTLA blocking antibody was approved by the Chinese NMPA and the US FDA for clinical application, and the phase I clinical study was

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.